Clinical Trial Update: Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations [Phase 2]

View source ↗

Summary

Phase 2 basket study of neratinib in solid tumors with somatic HER2 or EGFR exon 18 mutations was terminated; results posted in 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• neratinib (neratinib)

Snippet

Sponsor: Puma Biotechnology, Inc. | Conditions: Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations | Phase 2 | Status: TERMINATED | Results posted: 2024-03-12